Selank vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- Minutes (but effects persist for hours)
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- SubQ, Intranasal
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- 1–3 times daily
- 3 consecutive days per cycle
- Key Benefits
- Reduces anxiety without sedation
- Enhances memory and learning
- Improves focus and concentration
- Stabilizes mood
- Reduces physiological stress response
- May enhance motivation
- No addiction potential or withdrawal
- Fast-acting — effects within 20–30 minutes
- Approved clinically in Russia for anxiety disorders
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Mild sedation at higher doses (paradoxical)
- Fatigue (rare)
- Irritability during discontinuation (uncommon)
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —